Prescription drug abuse growing problem in Indiana
Prescription drugs are playing an increasing role in the drug-related crimes that are filling up Indiana's prisons, prison officials and prosecutors said.
Pharmaceutical
Articles
Amylin sues Lilly over drug development deal
Amylin Pharmaceuticals Inc. said Monday it filed a lawsuit against Eli Lilly and Co., accusing the larger drugmaker of breaking their commercialization deal for diabetes drugs by teaming with the German company Boehringer Ingelheim to develop and sell a competing product.
Lilly drug to detect Alzheimer’s criticized by consumer group
Eli Lilly and Co.’s Amyvid, an experimental imaging agent to detect signs of Alzheimer’s disease in the brain, shouldn’t be approved because of unreliable study results, a consumer-advocacy group said.
Two wins to bring Lilly modest sales
Finally, some new revenue. Eli Lilly and Co. will enjoy modest new sales later this year after U.S. regulators approved a new diabetes drug developed by a partner company, and another company nears approval on a drug that will produce royalties for the Indianapolis-based drugmaker.
FDA OKs new diabetes pill from Lilly, Boehringer
The Food and Drug Administration says it has approved a new diabetes pill from Boehringer Ingelheim and Eli Lilly for patients who can't control their blood sugar with older medicines.
Lilly teams with Medtronic on Parkinson’s treatment
Eli Lilly and Co. plans to use an implantable drug-delivery system made by Medtronic Inc. to precisely target patients' brains with an experimental drug for Parkinson’s disease.
Wellfount nabs $6M in venture capital
The Indianapolis-based institutional pharmacy, which serves long-term-care facilities, wants to expand its business nationally.
Analysts demand news on next Lilly blockbuster
Eli Lilly and Co. spends a lot of time these days telling the rest of the story—how well it’s doing in areas not connected to highly lucrative drugs about to see their patents expire. But for the most part, investors and analysts just want to know when the next blockbuster will be coming.
FDA wants further testing of Lilly pancreas drug
Eli Lilly and Co. Inc. said Friday that the FDA has asked the drugmaker to conduct another clinical trial of its proposed pancreas drug before it resubmits an application to have the drug approved for sale.
Feds: CVS to pay $17.5M over inflated Rx claims
The U.S. Justice Department says CVS Pharmacy Inc. has agreed to pay $17.5 million to settle allegations it overcharged Medicaid programs in 10 states, including Indiana.
Lilly’s Bydureon wins backing of European drug panel
The drug awaits final action by the European Commission, which has the authority to approve medicines for the European Union. The Commission usually makes a decision on CHMP recommendations within two to three months.
China making big gains in drug R&D jobs state covets
The total annual cost for one researcher at Lilly might run $300,000 to $350,000 a year. The figure at Crown Bioscience is one-third of that, said a company executive.
Antidepressants linked to narrowed arteries
The study included Eli Lilly and Co. drug Cymbalta, which racked up sales of $3.5 billion last year for the Indianapolis-based drugmaker.
Indiana college to break ground on pharmacy school
Northern Indiana's Manchester College plans to begin work this summer on the college's new $18 million pharmacy school.
Demographic shift steers Lilly’s Asian operations
China remains a small market for Eli Lilly and Co. It generated $320 million in sales for the company in 2010, just 1.3 percent of its $23 billion in sales worldwide. But Lilly has big ambitions in China and is racing to capitalize on its rapid economic growth.
Regulators delay approval of Lilly’s Alzheimer’s screen
The Food and Drug Administration said Lilly needs to create a training program to ensure brain scans are interpreted properly.
Trade agency to probe Lilly’s infringement claim
Eli Lilly and Co.’s patent-infringement claim over Hospira Inc.’s generic version of the cancer treatment Gemzar will be investigated by a U.S. trade agency with the power to block imports of the copycat drug.
Lechleiter: After the deluge, we’ll be fine
Eli Lilly and Co. CEO John Lechleiter visited Japan last week—three days before the massive earthquake—to deliver his tried-and-true message: Drug companies need to reinvent invention, governments needs to support innovation, and Lilly will be just fine after it has sustained the damage of the next three years.
Lilly confident of FDA approval for Amyvid, Lechleiter says
Eli Lilly and Co. CEO John Lechleiter said he’s confident of gaining U.S. regulatory approval for a drug to help identify plaque in the brain associated with Alzheimer’s disease.
Lilly suffers another bruise from Novo
The failure of its drug Bydureon to match the performance of Novo’s Victoza trims but doesn’t kill sales prospects for the highly touted diabetes drug.